Key Takeaways
- Moderna shares rallied more than 14% following positive Phase 3 data for intismeran autogene, its customized mRNA cancer treatment
- Clinical results demonstrated that intismeran paired with Merck’s Keytruda extended recurrence-free survival in melanoma patients versus Keytruda monotherapy
- Barclays lifted its Moderna price target from $48 to $125; Wolfe Research upgraded shares to Peer Perform from Underperform
- Wolfe Research forecasts peak revenue of $9.2B across four cancer types prior to revenue sharing with Merck
- Year-to-date gains for Moderna stock have reached 392%, raising questions about whether future potential is already embedded in the stock price
Shares of Moderna were changing hands near $154.94 during Tuesday’s session, climbing roughly 12% and claiming the top spot among S&P 500 gainers for the day. This latest advance follows a volatile pattern: an initial spike after the Phase 3 announcement last week, subsequent pullback as investors locked in profits, and now a renewed upward trajectory.
The driving force behind this momentum is the successful Phase 3 study of intismeran autogene, a personalized mRNA-based cancer treatment co-developed with Merck. Study findings revealed that combining intismeran with Merck’s immunotherapy drug Keytruda extended the duration patients remained disease-free compared to treatment with Keytruda as a standalone therapy. This marks a groundbreaking achievement as the first late-stage positive outcome for an mRNA cancer therapeutic.
The clinical study enrolled 1,100 participants who received the investigational vaccine following surgical excision of their melanomas. Intismeran is designed to recognize up to 34 tumor-specific neoantigensāabnormal proteins found on malignant cells that enable the immune system to locate and destroy cancer. Each treatment dose is customized by analyzing the genetic profile of a patient’s surgically removed tumor to identify its distinctive mutations.
The manufacturing timeline spans approximately six weeks from initial patient sample collection to final vaccine delivery. Patients can initiate Keytruda therapy during this production interval while awaiting their personalized treatment.
Wall Street Responds with Upgrades and Higher Targets
Barclays equity analyst Eliana Merle increased her firm’s Moderna price objective from $48 to $125 while maintaining an Equal Weight stance. She expressed confidence that intismeran has a favorable probability of successfully navigating the regulatory approval pathway.
Wolfe Research shifted its rating on Moderna from Underperform to Peer Perform on Tuesday. Analyst Alexandria Hammond observed that investor confusion regarding the actual definition and mechanism of cancer vaccines may have fueled the dramatic price movement observed last week.
BofA Securities and William Blair similarly raised their ratings on the biotech stock following the trial announcement. Wolfe’s financial model projects unadjusted peak revenue of $9.2B spanning four treatment indicationsāadjuvant melanoma, renal cell carcinoma (RCC), muscle-invasive bladder cancer (MIBC), and non-small cell lung cancer (NSCLC)ācalculated before accounting for the revenue-sharing arrangement with Merck.
Leerink Partners anticipates intismeran could deliver annual revenue in the low-single-digit billions by 2032. Merck’s internal projections estimate approximately $6 billion in sales by 2035.
Valuation Concerns Surface
Last Wednesday witnessed both Moderna and Merck adding more than $40 billion each to their respective market capitalizations in a single trading session. Given that a projected $10 billion revenue peak now supports roughly $40 billion in combined added market value, multiple analysts are questioning whether substantial upside remains or if current valuations already incorporate the opportunity.
Intismeran’s effectiveness across additional cancer types remains unproven. Nine active clinical trials are currently evaluating the treatment in various solid tumors, including lung, kidney, and pancreatic cancers. While analysts generally interpret the melanoma data favorably for these ongoing studies, positive outcomes aren’t guaranteed.
Wall Street analysts are targeting 2027 as a realistic commercialization timeline assuming interim data continues supporting efficacy. Moderna’s 52-week peak stands at $176.66.
On Tuesday, both Wolfe Research and Argus elevated their price targets on Merck as well, highlighting the strength of its development pipeline. Merck has been actively searching for its next major revenue driver as Keytruda approaches patent expiration.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
